Atlas Trials

A Study to Evaluate the Efficacy and Safety of Serplulimab in Combination With Chemotherapy and Concurrent Radiotherapy in Patients With Limited-Stage Small Cell Lung Cancer

Clinical trial NCT05353257 · ACTIVE_NOT_RECRUITING

Trial details

NCT number
NCT05353257
Sponsor
Shanghai Henlius Biotech
Status
ACTIVE_NOT_RECRUITING
Phase
Phase 3
Study type
INTERVENTIONAL
Limited-Stage Small Cell Lung Cancer
Start date
2022-05-17
Primary completion
2026-06-30
Enrollment
511

View on ClinicalTrials.gov

Track trials programmatically

Sponsors, conditions and status changes through the Atlas API.